Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark F Lew

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Communications Biology|February 17, 2024
Common mitochondrial deletions in RNA-Seq: evaluation of bulk, single-cell, and spatial transcriptomic datasetsAudrey A Omidsalar, Carmel G McCullough, Lili Xu, et al.
Archives of Neurology|March 10, 2010
Increased melanoma risk in Parkinson disease: a prospective clinicopathological studyJohn M Bertoni, John Philip Arlette, Hubert H Fernandez, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 4, 2017
A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's diseaseC Warren Olanow, Karl Kieburtz, Mika Leinonen, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 24, 2018
Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's diseaseHubert H Fernandez, James T Boyd, Victor S C Fung, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 30, 2014
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label resultsHubert H Fernandez, David G Standaert, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 24, 2015
Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trialsAnthony E Lang, Ramon L Rodriguez, James T Boyd, et al.
Clinical Parkinsonism & Related Disorders|July 28, 2021
Targeting neurons in the gastrointestinal tract to treat Parkinson's diseaseRobert A Hauser, Dean Sutherland, Juan A Madrid, et al.
American Journal of Human Genetics|March 29, 2002
PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD studyAnita L DeStefano, Mark F Lew, Lawrence I Golbe, et al.
Archives of Neurology|June 14, 2006
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD studyMei Sun, Jeanne C Latourelle, G Frederick Wooten, et al.
JAMA|February 11, 2015
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial, Karl Kieburtz, Barbara C Tilley, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Communications Biology|February 17, 2024
Common mitochondrial deletions in RNA-Seq: evaluation of bulk, single-cell, and spatial transcriptomic datasetsAudrey A Omidsalar, Carmel G McCullough, Lili Xu, et al.
Archives of Neurology|March 10, 2010
Increased melanoma risk in Parkinson disease: a prospective clinicopathological studyJohn M Bertoni, John Philip Arlette, Hubert H Fernandez, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 4, 2017
A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's diseaseC Warren Olanow, Karl Kieburtz, Mika Leinonen, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 24, 2018
Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's diseaseHubert H Fernandez, James T Boyd, Victor S C Fung, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 30, 2014
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label resultsHubert H Fernandez, David G Standaert, Robert A Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 24, 2015
Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trialsAnthony E Lang, Ramon L Rodriguez, James T Boyd, et al.
Clinical Parkinsonism & Related Disorders|July 28, 2021
Targeting neurons in the gastrointestinal tract to treat Parkinson's diseaseRobert A Hauser, Dean Sutherland, Juan A Madrid, et al.
American Journal of Human Genetics|March 29, 2002
PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD studyAnita L DeStefano, Mark F Lew, Lawrence I Golbe, et al.
Archives of Neurology|June 14, 2006
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD studyMei Sun, Jeanne C Latourelle, G Frederick Wooten, et al.
JAMA|February 11, 2015
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial, Karl Kieburtz, Barbara C Tilley, et al.
Pageof 5